Aprea Therapeutics reports second partial response in APR-1051 ACESOT-1051 trial

Reuters02-18

Aprea <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports second partial response in APR-1051 ACESOT-1051 trial

Aprea Therapeutics Inc. reported additional preliminary data from its ongoing Phase 1 ACESOT-1051 trial evaluating the investigational WEE1 kinase inhibitor APR-1051 in advanced solid tumors. The company said a patient with advanced endometrial cancer treated at the 220 mg dose level achieved an unconfirmed partial response at the first on-treatment scan, with a 50% reduction in target lesions and a CA-125 decrease from 362 U/mL to 47 U/mL; the tumor harbored a PPP2R1A mutation and the patient experienced Grade 1 adverse events. Aprea also summarized that 22 patients have been treated across 10–220 mg, with two unconfirmed partial responses (both PPP2R1A-mutated endometrial cancer) and five cases of stable disease reported to date. The company said a further trial update is expected in the second quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656458-en) on February 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612445164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612445164","market":"fut","top_or_hot":-1,"title":"Aprea Therapeutics reports second partial response in APR-1051 ACESOT-1051 trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aprea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports second partial response in APR-1051 ACESOT-1051 trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aprea Therapeutics Inc. reported additional preliminary data from its ongoing Phase 1 ACESOT-1051 trial evaluating the investigational WEE1 kinase inhibitor APR-1051 in advanced solid tumors. The company said a patient with advanced endometrial cancer treated at the 220 mg dose level achieved an unconfirmed partial response at the first on-treatment scan, with a 50% reduction in target lesions and a CA-125 decrease from 362 U/mL to 47 U/mL; the tumor harbored a PPP2R1A mutation and the patient experienced Grade 1 adverse events. Aprea also summarized that 22 patients have been treated across 10–220 mg, with two unconfirmed partial responses (both PPP2R1A-mutated endometrial cancer) and five cases of stable disease reported to date. The company said a further trial update is expected in the second quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656458-en) on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aprea Therapeutics reports second partial response in APR-1051 ACESOT-1051 trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAprea Therapeutics reports second partial response in APR-1051 ACESOT-1051 trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-18 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aprea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports second partial response in APR-1051 ACESOT-1051 trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aprea Therapeutics Inc. reported additional preliminary data from its ongoing Phase 1 ACESOT-1051 trial evaluating the investigational WEE1 kinase inhibitor APR-1051 in advanced solid tumors. The company said a patient with advanced endometrial cancer treated at the 220 mg dose level achieved an unconfirmed partial response at the first on-treatment scan, with a 50% reduction in target lesions and a CA-125 decrease from 362 U/mL to 47 U/mL; the tumor harbored a PPP2R1A mutation and the patient experienced Grade 1 adverse events. Aprea also summarized that 22 patients have been treated across 10–220 mg, with two unconfirmed partial responses (both PPP2R1A-mutated endometrial cancer) and five cases of stable disease reported to date. The company said a further trial update is expected in the second quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656458-en) on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL8bnrb7:1","article_id":"2612445164","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612445164","pubTimestamp":1771419721,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aprea Therapeutics Inc. reported additional preliminary data from its ongoing Phase 1 ACESOT-1051 trial evaluating the investigational WEE1 kinase inhibitor APR-1051 in advanced solid tumors. The company said a patient with advanced endometrial cancer treated at the 220 mg dose level achieved an unconfirmed partial response at the first on-treatment scan, with a 50% reduction in target lesions and a CA-125 decrease from 362 U/mL to 47 U/mL; the tumor harbored a PPP2R1A mutation and the patient experienced Grade 1 adverse events. Aprea also summarized that 22 patients have been treated across 10–220 mg, with two unconfirmed partial responses  and five cases of stable disease reported to date. The company said a further trial update is expected in the second quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","APRE":"Aprea Therapeutics, Inc.","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4112":"金融交易所和数据","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC"},"translate_title":"Aprea Therapeutics报告APR-1051 ACESOT-1051试验第二次部分缓解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"APRE":0.9},"content_text":"Aprea Therapeutics reports second partial response in APR-1051 ACESOT-1051 trial\n    \n\n        Aprea Therapeutics Inc. reported additional preliminary data from its ongoing Phase 1 ACESOT-1051 trial evaluating the investigational WEE1 kinase inhibitor APR-1051 in advanced solid tumors. The company said a patient with advanced endometrial cancer treated at the 220 mg dose level achieved an unconfirmed partial response at the first on-treatment scan, with a 50% reduction in target lesions and a CA-125 decrease from 362 U/mL to 47 U/mL; the tumor harbored a PPP2R1A mutation and the patient experienced Grade 1 adverse events. Aprea also summarized that 22 patients have been treated across 10–220 mg, with two unconfirmed partial responses (both PPP2R1A-mutated endometrial cancer) and five cases of stable disease reported to date. The company said a further trial update is expected in the second quarter of 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656458-en) on February 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612445164","isCrawlerRequest":true}